A Meta-Analysis on the Efficacy and Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction

@article{Djavan1999AMO,
  title={A Meta-Analysis on the Efficacy and Tolerability of $\alpha$1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction},
  author={Bob Djavan and Michael J. Marberger},
  journal={European Urology},
  year={1999},
  volume={36},
  pages={1 - 13}
}
Objective: To assess whether the α1-adrenoceptor antagonists currently available for the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) (alfuzosin, terazosin, doxazosin and tamsulosin) can be distinguished with regard to clinical efficacy and/or tolerability. Methods: Up-to-date analysis of clinical placebo-controlled or direct comparative studies with α1-adrenoceptor antagonists in patients with LUTS suggestive of BPO derived from a MEDLINE… 

Figures and Tables from this paper

Comparison of 7 α(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia:a short-term crossover study.

TLDR
It is found that each of the 7 α1AR antagonists has its own supporters and the one-week crossover study was useful in identifying the best agent for the treatment of each individual with LUTS.

α1-Blocker Therapy for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: What Are the Relevant Differences in Randomised Controlled Trials?

Randomised controlled trials (RCTs) provide the best available external evidence for the use of α 1 -blockers in treating lower urinary tract symptoms (LUTS) suggestive of benign prostatic

Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.

TLDR
Overall, data show overall that tamsulosin clearly offers advantages over other alpha(1)-adrenoceptor antagonists in terms of the need for a single daily dose only, and its low potential for hypotensive effects or interference with concomitant antihypertensive therapy.

Medical Treatment Modalities for Lower Urinary Tract Symptoms: What Are the Relevant Differences in Randomised Controlled Trials?

TLDR
Short-term, direct comparative studies suggest that, like finasteride, α1-adrenoceptor antagonists have a comparable positive effect on disease progression, and more comparative information is needed on the long-term efficacy, tolerability, and effectiveness of medical treatments for LUTS.

Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms.

TLDR
Alpha-Blockers remain one of the mainstays in the treatment of male LUTS and clinical BPH, they exhibit an early onset of efficacy (within less than 1 week), maintain such improvements in open-label and controlled trials for up to 5 years, and have been shown to prevent symptomatic progression.

alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.

TLDR
The alpha-blockers alfuzosin, terazosin and tamsulosin are effective for treating symptoms suggestive of bladder outlet obstruction in patients presenting with lower urinary tract symptoms but not for treating the obstruction.

Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia

TLDR
Evidence suggests that this combination of tadalafil and finasteride may be particularly effective in reducing treatment-related sexual adverse events associated with 5-ARI treatments.

Effects of alpha-1-adrenergic receptor subtype-selective antagonists on lower urinary tract function in rats with bladder outlet obstruction

TLDR
Urinary frequency is increased in rats with bladder mass 500 mg, and the combined α1a/α1dAR antagonist tamsulosin reduces urinary frequency more than the α1AAR selective antagonist 5MU, which supports the hypothesis that the α 1dAR is important in mediating irritative symptoms.
...

References

SHOWING 1-10 OF 93 REFERENCES

Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses.

TLDR
Tamsulosin was as effective as terazosin in treating urinary outflow obstruction associated with BPH, but had a markedly better safety profile.

Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups.

TLDR
Results from these five clinical trials demonstrate doxazosin is effective and safe and well tolerated in both normotensive and hypertensive patients with BPH.

Tamsulosin, a selective α1c‐adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH)

TLDR
Tamsulosin 0.4 mg once daily is safe, well tolerated and clinically effective in improving symptoms and urinary flow rate in patients with symptomatic BPH.

Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.

TLDR
Tamsulosin 0.4 mg once daily is safe, well-tolerated and improves both the symptoms and urinary flow rate in patients with benign prostatic obstruction (symptomatic BPH).

Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia)

TLDR
Tamsulosin is the first adrenoceptor antagtermed symptomatic benign prostatic hyperplasia (BPH) that is selective for the a 1A -subtype; this specificity may explain its lack of statistically significant impact on blood pressure.

A Double-Blind Comparison of Terazosin and Tamsulosin on Their Differential Effects on Ambulatory Blood Pressure and Nocturnal Orthostatic Stress Testing

TLDR
Once-daily dosing of TAM after breakfast at a fixed dose level (0.4 mg) offers a more efficient protection against undesired cardiovascular extension effects in the normotensive elderly treated for LUTS suggestive of BPO than the usually recommended treatment schedule of TER with step-up doses administered at night.

Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy.

TLDR
The treatment of BPH with terazosin produced a significant improvement in mean flow rate and peak flow rate; there were no statistically significant differences in the analysis of symptomatic responses between the groups of patients treated with terrazosin or placebo.

a-BLOCKADE IN THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA

TLDR
Tolerance to treatment appeared to develop in a large proportion of patients after 6 months of therapy, however, for patients who benefit from long-term use of a-blockers effective treatment might be maintained for years.
...